Trump’s Psychedelic Push

Trump's Psychedelic Push President Donald Trump signed an executive order on April 18, 2026, initiating reforms to accelerate access to psychedelic drug treatments in the United States. This directive aims to expedite the federal review process for substances like ibogaine, which has garnered significant attention from combat veterans and conservative lawmakers for its potential in treating severe mental health conditions such as post-traumatic stress disorder (PTSD) and chronic depression. The administration's move signals a shift towards exploring alternative therapeutic avenues, acknowledging the urgent need for innovative solutions in mental healthcare. - The executive order specifically directs the Food and Drug Administration (FDA) to fast-track the review of certain psychedelic drugs, including ibogaine. - Ibogaine, currently classified under the federal government's most restrictive category for illegal, high-risk drugs, has been championed by US military veteran groups for its reported efficacy in treating PTSD. - The FDA is also taking proactive steps to clear regulatory hurdles for the first-ever human clinical trials of ibogaine to be conducted within the United States. - This policy shift aligns with earlier commitments from Health Secretary Robert F. Kennedy Jr. and other administration officials to ease access to psychedelics for medical purposes, an issue that has achieved rare bipartisan support. - Despite the promising therapeutic potential, significant concerns persist regarding ibogaine's known cardiovascular toxicity, a factor that previously led the National Institutes of Health to discontinue funding research on the drug in the 1990s due to safety risks. Why this poll exists: Users are being asked to vote on their opinion regarding the Trump administration's executive order to accelerate the review and research of psychedelic drugs for medical treatment, considering both potential benefits and safety concerns. Source: The Guardian, PBS News